Rocket's gene therapy for heart disease shows promise in children/adults in phase 1 trial

Sep. 30, 2022 7:16 AM ETRocket Pharmaceuticals, Inc. (RCKT)By: Ravikash, SA News Editor1 Comment

DNA

peterschreiber.media/iStock via Getty Images

Rocket Pharmaceuticals (NASDAQ:RCKT) said its gene therapy RP-A501 was safe, well tolerated and showed clinical benefit in two children and four adults in a phase 1 trial to treat Danon Disease (DD).

DD is a rare genetic

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.